Our Pricing

NHS Mounjaro Weight Loss UK Comparison

Understanding your NHS Mounjaro weight loss UK comparison options helps you make informed decisions about accessing this licensed treatment. At Cured Pharmacy, we provide transparent pricing from £135.00 UK prescriber consultations within 3 minutes, and genuine MHRA-licensed medications delivered discreetly to your door.

How NHS Mounjaro Weight Loss UK Comparison Works

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in adults with a BMI of 30 or above, or 27 with weight-related health conditions [1]. Unlike single-pathway treatments, tirzepatide activates two complementary hormone systems that regulate appetite, food intake, and blood glucose levels, producing superior clinical outcomes in randomised controlled trials.

In the landmark SURMOUNT-1 trial, participants receiving the 15mg maintenance dose achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This represents the highest weight loss observed in any GLP-1 receptor agonist trial to date, establishing Mounjaro as a clinically significant option for patients who meet prescribing criteria.

NHS availability of Mounjaro for weight management remains limited due to NICE guidance restrictions and regional formulary decisions. Many UK patients now access treatment through registered online pharmacies, where clinical assessment by UK prescribers ensures safe, appropriate prescribing outside traditional NHS pathways.

Mounjaro vs Wegovy: Clinical Efficacy Comparison

Both Mounjaro and Wegovy are injectable treatments approved by the MHRA for chronic weight management, but they operate through different receptor mechanisms. Wegovy (semaglutide) activates only GLP-1 receptors, while Mounjaro activates both GIP and GLP-1 receptors simultaneously [1][2].

Head-to-head trial data from SURPASS-2 demonstrated that tirzepatide 15mg produced significantly greater weight reduction than semaglutide 1mg in patients with type 2 diabetes, with average reductions of 11.2kg versus 5.7kg respectively over 40 weeks [3]. While direct comparison trials in weight management populations are ongoing, current evidence suggests tirzepatide may offer enhanced efficacy for eligible patients.

Your UK prescriber will assess your medical history, current medications, and weight loss goals to determine which treatment aligns with your clinical needs. Both medications require once-weekly subcutaneous injection and gradual dose escalation to minimise gastrointestinal side effects.

Choosing Between Injectable Options

Clinical factors influencing treatment selection include previous response to weight loss interventions, tolerance of gastrointestinal side effects, and presence of comorbidities such as type 2 diabetes or cardiovascular disease. Patients with established cardiovascular disease may benefit from semaglutide's proven cardiovascular outcomes data, while those seeking maximum weight reduction may be suited to tirzepatide subject to prescriber approval [2][3].

Understanding Mounjaro Pricing and Accessibility

Mounjaro is available at Cured Pharmacy from £135.00, with transparent upfront pricing displayed before your clinical consultation begins. This contrasts with NHS pathways where access depends on strict eligibility criteria, local commissioning decisions, and often lengthy waiting lists for specialist weight management services.

Private prescription pathways through UK-registered online pharmacies offer several advantages: immediate clinical assessment by qualified prescribers, no GP referral required, discreet home delivery, and guaranteed access to licensed stock. All Mounjaro pens dispensed by Cured Pharmacy are genuine UK-licensed products sourced through regulated pharmaceutical wholesalers, ensuring full MHRA compliance and patient safety.

Treatment duration typically spans 12-24 months for optimal weight loss outcomes, with ongoing prescriber review every 8-12 weeks to monitor efficacy, tolerability, and appropriate dose titration. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical protocols to ensure safe, evidence-based prescribing practices across our registered pharmacy (GPhC 9012511).

What's Included in Your Treatment Package

Every Mounjaro prescription includes free clinical consultation with a UK-registered prescriber, discreet packaging with no external pharmacy branding, and ongoing access to our clinical team for treatment queries. Your prescriber will provide detailed injection technique guidance, dietary modification advice, and clear protocols for managing potential side effects such as nausea or constipation.

Alternative Weight Loss Treatments Available

Beyond Mounjaro, several MHRA-licensed weight management medications offer effective alternatives depending on your clinical profile and preferences. Wegovy (semaglutide) provides once-weekly injectable treatment with robust clinical trial data demonstrating average weight reductions of 14.9% over 68 weeks in the STEP-1 trial [2].

Saxenda (liraglutide) offers a daily injection option for patients who prefer more frequent dosing or have contraindications to newer GLP-1 receptor agonists. Clinical trials showed average weight loss of 8% over 56 weeks when combined with reduced-calorie diet and increased physical activity [4].

Oral medications including Orlistat provide non-injectable alternatives by reducing dietary fat absorption in the gastrointestinal tract. While typically producing more modest weight reductions of 5-10%, oral treatments suit patients with needle phobia or those seeking lower-cost options. All prescription weight loss medications available at Cured Pharmacy require clinical assessment to ensure appropriate prescribing and exclude contraindications.

How to Start Your Mounjaro Treatment

Beginning treatment requires completion of a comprehensive online clinical assessment reviewed by a UK-registered prescriber. The consultation covers your medical history, current medications, previous weight loss attempts, and any contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1].

If approved, your prescription is dispensed by our GPhC-registered pharmacy team and dispatched via tracked courier for discreet delivery. Initial dosing begins at 2.5mg once weekly for four weeks, then increases to 5mg for four weeks, with further escalation to 7.5mg, 10mg, 12.5mg, or 15mg based on tolerability and weight loss response [1].

Your prescriber will schedule follow-up reviews every 8-12 weeks to assess treatment efficacy, monitor for adverse effects, and adjust dosing as clinically indicated. Discontinuation should be considered if patients fail to achieve at least 5% weight loss after 16 weeks on the maximum tolerated dose, in line with NICE guidance for GLP-1 receptor agonists in weight management [5].

What to Expect During Treatment

Most patients experience gradual, sustained weight reduction over 6-12 months, with gastrointestinal side effects such as nausea, diarrhoea, or constipation most common during dose escalation phases. These typically resolve within 2-4 weeks as your body adapts to each new dose. Staying well-hydrated, eating smaller meals, and avoiding high-fat foods can minimise discomfort during the adjustment period.

Safety Considerations and Contraindications

Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or previous serious hypersensitivity to tirzepatide [1]. It should be used with caution in patients with severe renal impairment, active gallbladder disease, or history of pancreatitis.

Common adverse effects include nausea (affecting up to 30% of patients), diarrhoea, vomiting, constipation, and abdominal pain, typically mild to moderate in severity and decreasing over time [1]. Rare but serious risks include acute pancreatitis, acute kidney injury secondary to dehydration, and hypoglycaemia when used alongside other glucose-lowering medications.

Pregnant or breastfeeding women should not use Mounjaro, and females of childbearing potential should use effective contraception during treatment and for at least four weeks after discontinuation. Your UK prescriber will conduct thorough medical screening to identify any contraindications before approving treatment, ensuring safe and appropriate prescribing in accordance with MHRA licensing and professional guidelines.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
5. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management. NICE guideline [CG189]. https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.